Answers are grounded in this paper and cite their sources.
Pembrolizumab demonstrated promising antitumor activity and a manageable safety profile in patients with advanced, PD-L1-positive SGC.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: